Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
GYREthis companyGyre Therapeutics, Inc.	$4.69	125.4×	5.95×	5.41×	35.15×	-115.1%	95.4%	9.9%	4.3%	4.7%	5.3%	-0.0%	0.01×	-2.14×	0×	5.6×	0.0%	1	8.69	2	C
GALTGalectin Therapeutics Inc.	$3.37	-8.67×	-2.11×	0×	-16.28×	-156.0%	0.0%	0.0%	0.0%	24.4%	-174.3%	-9.0%	-1.06×	-4.95×	-2.74×	2.42×	0.0%	2	-55.48	2	C
PLRXPliant Therapeutics, Inc.	$0.81	-0.5×	0.41×	0×	-0.4×	-67.7%	0.0%	0.0%	0.0%	-82.4%	-71.4%	-171.9%	0.16×	0.11×	-58.65×	12×	0.0%	2	-6.55	2	B-
SRZNSurrozen, Inc.	$32.38	-0.7×	-0.9×	48.61×	-0.36×	-60.9%	84.6%	-1210.6%	-6960.8%	128.9%	-46.7%	-18.0%	-0.04×	0.34×	0×	9.22×	0.0%	1	-15.27	2	C+
TVRDTvardi Therapeutics, Inc.	$1.07	-1.75×	1.52×	0×	-0.63×	179.3%	0.0%	0.0%	0.0%	-87.0%	-126.5%	-73.7%	0.01×	1.13×	0×	2.86×	0.0%	1	-13.58	3	B-
Peer median	—	-1.22×	-0.24×	0×	-0.52×	-64.3%	0.0%	0.0%	0.0%	-29.0%	-98.9%	-45.8%	-0.01×	0.23×	-1.37×	6.04×	0.0%	2	-14.43	2	—